WeChat Share

Boston BioForum 2017

CABA 10th Annual Conference

Presented by

Chinese-American BioMedical Association (CABA)


CABA members: FREE; Non-members: $30. On-site membership registration available ($30 annual membership fee due).



Conference Organizing Committee:

Chair Kevin Fang, Ph.D.

Co-Chairs Jian Shao, MBA; Lan Cao, Ph.D.; Bo Ying, Ph.D.


For information about CABA and upcoming events, please check CABA Web site: www.cabaweb.org.


09:00 - 10:00 am Registration / Social Networking 

10:00 - 10:05 am Opening Remarks, Kevin Fang, Ph.D., Symposium Chair, President-Elect, CABA 

10:05 - 10:15 am Introduction of CABA, Eric Shi, Ph.D., President, CABA 


Session I – Novel Therapies for Cancer and Neurological Diseases 

SESSION CHAIR: Lan Cao, Ph.D. and Cindy Yang, MBA. 

10:15 - 10:50 am Samarth Kulkarni, Ph.D., Chief Business Officer, CRISPR Therapeutics. “CRISPR-based Therapeutics: Making it a Reality in Asian Markets” 

10:50 - 11:25 am Ken LéClair, VP, Technical Development and Manufacturing, Editas Medicine. “Development of Cell and Gene-Edited Products” 

11:25-12:00 pm Carmen Bozic, M.D. SVP Global Develop, Biogen. “Innovations in Intrathecal Antisense Oligonucleotide Therapy for Neurological Diseases” 


LUNCH AND VENDOR SHOW: 12:00 - 1:30 pm (Lunch Provided on Site) 



12:45 - 1:05 pm John Yao, Ph.D., Co-founder and CEO, TC Scientific Inc. “A CRO’s View of the Pharma Landscape” hosted by Ellen Fan, MSc 


SESSION II – Global Innovation, Investment, and Entrepreneurship 


1:30 - 2:05 pm Hui Cai, Ph.D., VP of Corporate Alliances and Head of Communications, WuXi AppTec. “Platform and Ecosystem for R&D Transformation” 

2:05 - 2:40 pm James Yang, Ph.D., President and CEO, Abpro-China. “Strategic Partnership for Success in Biologics 

2:40 - 3:15 pm Yongzhong Wang, Ph.D., President of Pharmaceuticals and Executive VP of Simcere Pharmaceutical Group. “Innovations across the Border, a Personal Journey” 

3:15 - 3:50 pm Lynn Yang, MBA, General Manger, Sequoia Capital “Sequoia China Healthcare Investment Strategy” 




SESSION III - Global Pharma Trends, CFDA Regulatory Reform and Scientific Advancement in PD-1 Research 

SESSION CHAIRS: Wendy Yang, MBA and Susan Qu, Ph.D., MBA 

4:20 - 4:55 pm Kenneth Kaitin, Ph.D., Professor and Director, Tufts Center for the Study of Drug Development, Tufts University School of Medicine “The Global Landscape for Pharmaceutical R&D: Current Trends - Future Opportunities” 

4:55 - 5:30 pm XinYu Weng, Ph.D., MBA, First Secretary of the Embassy of the China to the USA. “Overview of CFDA Drug Regulatory Reform” 

5:30 - 6:05 pm Gordon Freeman, Dana-Farber Cancer Institute, Professor, Medicine, Harvard Medical School. "PD-1 Cancer Immunotherapy" 

6:05 - 6:10 pm Closing Remarks

6:10 - 8:30 pm 10th Anniversary Evening Celebration

Key Feature: Former Presidents' Documentary Film

6:50 - 7:50 pm Dinner

7:50 - 8:30 pm Performances



Samarth Kulkarni, PhD
CRISPR Therapeutics , Chief Business Officer
Samarth (Sam) Kulkarni is the Chief Business Officer of CRISPR Therapeutics since 2015. At CRISPR, Sam is responsible for Corporate Strategy, Business Development, and Investor Relations. Sam has significant expertise in strategy and operations in biotech and a wide range of related cutting-edge therapeutic technologies. He was previously a Partner at McKinsey and Company, where he had a leading role in the Pharmaceutical and Medical products practice. While at McKinsey, Sam co-led the biotech practice and served a number of biotechnology companies on topics ranging from strategy to operations. Additionally, he led initiatives in areas such as personalized medicine and immunotherapy, where he co-authored several publications. Sam received his Ph.D. in Bioengineering and Nanotechnology from the University of Washington and a B. Tech. from the Indian Institute of Technology. While at the University of Washington, he conducted research in the delivery of biological drugs and in the field of molecular diagnostics, and published in leading journals.
Ken LeClair
Editas Medicine, VP, Technical Development and Manufacturing
Ken LeClair received his undergraduate degree from Bowdoin College and a Ph.D. in Immunobiology from Yale University. He did a postdoc at the MIT Center for Cancer Research and had an academic appointment as Assistant Professor of Medicine in the Immunology Division of the Beth Israel Deaconess Medical Center at the Harvard Medical School. Ken left academics and worked at several small biotech companies in the Boston area before joining Novartis in 2008. Ken spent the first 4 years at Novartis performing developability assessments for biologics candidates coming into Development from the NIBR discovery research organization. He then performed the technical diligence for the CART immunotherapy collaboration with UPenn and helped to establish the Novartis Cell and Gene therapy Unit, until it was rec ently reorganized. He joined Editas Medicine late in 2016 and is working to help bring CRISPR-based therapies to the clinic and to market.
Carmen Bozic, MD
Biogen, SVP of Global Development
Carmen Bozic MD is Senior Vice President of Global Development at Biogen, accountable for developing, obtaining and maintaining regulator y approval of therapies in Biogen’s therapeutic focus areas of Neurodegenerative and Rare Diseases. Dr. Bozic is an experienced drug development leader with 18 years of progressively increasing responsibilities in the biopharmaceutical industry. Her Global Development organization includes Regulatory Affairs, Safety and Benefit-Risk Management, Biometrics, Global Clinical Operations, R&D Compliance, Medical Writing, as well as Development Sciences in Japan. Previously, she oversaw Clinical Development in the Neurology, Immunology and Hematology Therapeutic Areas as well as Preclinical Safety and was the former SVP and Global Head of Safety and Benefit-Risk Management at Biogen. In her leadership roles at Biogen, Dr. Bozic has overseen regulatory filings and approvals of multiple therapies, including TYSABRI (natalizumab), AVONEX (interferon beta-1a) pre-filled syringe and auto-injector, TECFIDERA (dimethyl fumarate), PLEGRIDY (pegylated interferon beta-1a) and ZINBRYTA (daclizumab) for the treatment of multiple sclerosis, as well as ELOCTATE (Factor VIII Fc fusion protein) and ALPROLIX (Factor IX Fc fusion protein) for the treatment of severe Hemophilia A and B in multiple countries. In addition, in her role as SVP and Global Head of Safety and Benefit-Risk Management at Biogen for several years, she built a world-class organization accountable for patient safety and epidemiology in the pre and post-approval pipeline and addressed complex issues in safety and benefit-risk management. While in that role she led the development of the risk management plan for TYSABRI (natalizumab) and presented on this topic at an FDA Advisory Committee, leading to the approval of TYSABRI for the treatment of multiple sclerosis. She has served as the industry representative to the FDA’s Risk Communication Advisory Committee and is a member of PhRMA’s Clinical and Preclinical Development committee. She is a member of the Board of Managers at BioMotiv. She received an MD degree and did her residency in internal medicine at McGill university in Montreal, Canada, completed a fellowship in Pulmonary and Critical Care Medicine at Brigham and Women’s Hospital in Boston, and was an Associate Physician at Beth Israel Deaconess Medical Center and Harvard Medical School before joining the biopharmaceutical industry. Dr. Bozic is a frequent lecturer and speaker on benefit-risk and other drug development topics nationally and internationally.
John Yao
TC Scientific , CEO
Dr. Junzhi (John) Yao received his PhD degree in chemistry from Wuhan University. After graduation, he joined the Department of Chemistry at Wuhan University in July 1994 as an Assistant Professor. From 1995 to 1997, Dr. Yao worked at Hong Kong University of Science and Technology as a Visiting Scholar. He obtained Postdoctoral Research training at the Department of Chemistry at Southern Methodist University in Dallas, USA f rom 1997 to 1999 and conducted postdoctoral research at the Department of Chemistry and Faculty of Pharmacy at the University of Manitoba, Canada from 1999 to 2001. Dr. Yao joined Medicure Inc. in Winnipeg, Canada as a Research Sci entist conducting drug discovery research for cardiovascular diseases and stroke. His contract research experience includes a 3-year collaboration effort with Pfizer. In 2009, Dr. Yao co-founded TC Scientific Inc. in Edmonton, Alberta, Canada. He has been the CEO of TC Scientific since 2009. Under his leadership, TC Scientific has become one of the top CRO's in Canada.
Hui Cai
WuXi App Tec, Vice President of Corporate Alliances
Dr. Hui Cai joined WuXi AppTec in 2009 as Vice President of Business Development, and is currently Vice President of Corporate Alliances, and Head of PR and Corporate communications. Prior to WuXi, Dr. Cai spent 10 years at Johnson & Johnson Pharmaceutical Research and Development leading multiple drug discovery programs in the therapeutic areas of inflammation and autoimmune diseases. She is a co-author and co-inventor to over 40 scientific publications and issued or pending patents. Dr. Cai is a Councilor of the American Chemical Society (ACS) and a member of ACS national committee on Chemistry and Public Affairs. She is also a member of the A dvisory Council of UCSD IRPS 21th Century China Program, and a member of BayHelix. In her past capacity, she served as a Commissioner at the City of San Diego Science and Technology Commission, Chair of SABPA, and President of SDCA. Dr. Cai received her BS and MS in Chemistry from Peking University, PhD from The Scripps Research Institute, and MBA from UCSD Rady School of Management as a DLA Piper – Athena Scholar.
James Yang
Abpro-China, President / CEO
Dr. James (Jianguo) Yang has over 20-year extensive experience in biopharma industry. Currently, Dr. Yang is President / CEO Abpro-China (Abpro, a Biotech company based in Boston area, USA). Before joining Abpro, Dr. Yang was CSO / VP Biologics in Qilu Pharmaceuticals, and also had scientific leadership positions in several global 500 pharmaceutical companies, including in Abbott Lab Pharma Division (current AbbVie), MedImmune /AstraZeneca, Genzyme / Sanofi. Dr. Yang has published numerous patents and scientific papers, and is an editor advisor and reviewer for Bioprocess International (Journal), and Executive Director, Sino-America Pharmaceutical Association-NE (2012-2014), and also reviewer for several scientific journals. As international recognized scientist in biopharma Industry, Dr. Yang is a frequently-invited speaker for inter national biotech/biopharma conferences. Dr. Yang got his Ph.D. in cell/molecular biology from Illinois Institute of Technology, USA.
Yongzhong Wang, Ph.D.
Dr. Yongzhong Wang is the President of Pharmaceuticals and Executive VP of Si, President
Dr. Yongzhong Wang is the President of Pharmaceuticals and Executive VP of Simcere Pharmaceutical Group. He manages API manufacturing, sales and international regulatory affairs o f the group, as well as Simcere Europe. Prior to Simcere, Dr. Wang was the CEO of Chengdu Kanghong Biotechnology Co., Ltd, a leading biotech company in China. He was instrumental for the development and commercialization of Conbercept, a fusion protein approved in 2013 in China as the longest lasting wAMD drug in the world. As CEO, he led the company to achieve triple digit growth and transi tioned the previously single product-centric company to a full-fledged biotech business covering integrated R&D of multiple products, commercial manufacturing & distribution, and international development. In 2016, he successfully led his team to open a FDA IND for Conbercept to bypass Phases 1&2 and directly enter Phase 3 in the US, a rarity for novel biologics originally developed outside the US. Prior to Kanghong Biotech, Dr. Wang worked at Genzyme in Cambridge, MA, where he led critical projects for a number of innovative products including MACI, the first tissue engineering product approved by the FDA for adult cartilage repair. While at Genzyme, Dr. Wang had two US/PCT patents and supported international marketing. He earned his Ph.D at Tufts University and had 10 peer reviewed publications with totally over 3000 citations.
Lynn Yang
Sequoia Capital , General Manager
Lynn Yang, focusing on healthcare investment. Prior to joining Sequoia Capital in May,2015, Lynn worked at Legend Capital healthcare team. Lynn accomplished investment deals in different area of healthcare industry. Before setting her foot in venture capital, Lynn worked as business development manager in Johnson & Johnson and product manager at GE Healthcare. Mrs. Yang holds a MBA from Duke University and Master of Clinical Science from Huazhong Technology University.
Kenneth I. Kaitin
Tufts Center for the Study of Drug Development , Professor and Director
Dr. Kaitin is Professor of Medicine and Director of the Tufts Center for the Study of Drug Development at Tufts University School of Medicine. Dr. Kai tin also holds appointments as Advisory Professor at Shanghai Medical College of Fudan University in China; Visiting Executive at the Tuck School of Business at Dartmouth Coll ege; and faculty of the European Center for Pharmaceutical Medicine at the University of Basel. A former president of the Drug Information Association, Dr. Kaitin is currently editor-in-chief of Expert Review of Clinical Pharmacology and serves as an expert consultant to the U.S. Department of Defense on bioterror countermeasure initiatives. An internationally recognized expe rt in drug development science and policy, Dr. Kaitin writes and speaks regularly on factors that contribute to the slow pace and high cost of drug development and efforts to improve R&D efficiency, and he has provided public testimony before the U.S. Congress on drug development and policy issues. Dr. Kaitin serves on several public, private, and not-for-profit boards of directors. He received a BS from Cornell University and PhD in pharmacology from the University of Rochester.
Weng Xinyu, Ph.D
the Embassy of the People’s Republic of China to the USA, First Secretary
Weng Xinyu, Ph.D, is First Secretary of the Embassy of the People’s Republic of China to the United States of America. As the primary point of contact for China Food and Drug Administration (CFDA) in the U.S., Dr. Weng is committed to strengthening bilateral food and drug regulatory cooperation between China and the U.S., and reaching out to the U.S. food and drug industry. Before being transferred to the Chinese mbassy in Washington DC, Dr. Weng served as a Division Director in the Department of International Cooperation, CFDA since May 2013. In this capacity, he was responsible for bilateral cooperation with foreign food and drug regulatory authorities, non-governmental organizations, as well as foreign food and drug manufacturers. Dr. Weng was essential in the negotiations of the Implementing Arrangement between CFDA and US FDA regarding the cooperative mechanism of regulatory staff in 2014. Prior to that, he served as Division Director in the Department of Drug Safety and Supervision, State Food and Drug Administration (SFDA). In that c apacity, he coordinated implementation of the 2010 Edition Chinese Good Manufacturing Practices (GMP) for pharmaceutical products, and was an active participant in the International Conference of Drug Regulatory Authorities (ICDRA) organized by the World Health Organization. Dr. Weng joined State Drug Administration (SDA) in 1998, holding various positions including Deputy Division Director in the Department of Drug Registration, and the Department of Drug Safety and Supervision. He was involved in carrying out traditional medicine registration and Good Clinical Practices (GCP) inspection, and in drafting Good Agricultural Practices (GAP) for herbal medicines. Dr. Weng got his Ph.D from Shenyang Pharmaceutical University. He completed his MBA degree at the Birmingham University of the United Kingdom.
Gordon J. Freeman, Ph.D.
Harvard Medical School, Professor of Medicine
Gordon J. Freeman, PhD works in the Department of Medical Oncology at Dana-Farber Cancer Institute and is Professor of Medicine at Harvard Medical School. Dr. Freeman earned his BA in Biochemistry and Molecular Biology, and PhD in Microbiology and Molecular Genetics from Harvard University. His research has identified the major pathways that control the immune response by inhibiting T cell activation (PD-1/PD-L1 and B7-2/CTLA-4) or stimulating T cell activation (B7-2/CD28). In 2000, Dr. Freeman discovered PD-L1 and PD-L2, and showed they were ligands for PD-1, thus defining the PD-1 pathway and the drug target: block the interaction. He showed the function of PD-1 was to inhibit immune responses and that blockade enhanced immune responses. He showed that PD-L1 is highly expressed on many solid tumors such as breast and lung, as well as some hematologic malignancies and allows these tumors to inhibit immune attack. He received the 2014 William B. Coley Award for Distinguished Research in Tumor Immunology for this work that led to development of PD-1 pathway blockade for cancer immunotherapy.

Date and Time

2017-05-06 10:00 - Start

2017-05-06 18:00 - End

  • 2345 Commonwealth Ave , NEWTON  MA  02466


Type Sales End Price Quantity

CABA Active Members

2017-05-06 18:00 $0

Registration-Regular/Membership Renewal

2017-05-06 18:00 $30


2017-05-06 18:00 $15


2017-05-06 18:00 $60


2017-05-06 18:00 $45

About CABA

Chinese-American BioMedical Association (CABA) is a 501(C)(3) not-for-profit professional organization registered in Massachusetts since May 2007. CABA is committed to promote public awareness of advancement in the pharmaceutical and biomedical industry, professional interactions in the fields of life sciences, global biomedical innovations and business development. As the majority of its members are scientists with Chinese heritage, CABA will operate in two important areas. One is to serve as a platform for its members to develop and advance their careers in the US pharmaceutical and biomedical industry, the other is to serve as a bridge to connect members including corporate members with the scientific and business resources in China thus facilitating collaboration between the pharmaceutical and biomedical industries across continents. To fulfill these goals, we will organize scientific and business symposia, conferences, workshops, in US and China, as well as social events to promote networking and communication among members. We will bring together members, scientists, professionals, government officials and business leaders across the continents under a collaborative environment and achieve their best potentials. 

CABA is a volunteer-based society. We rely on members to contribute their time and efforts to build the organization. We rely on corporate members and sponsors to raise fund to support the above activities. We value integrity, honesty, professionalism, community service, scientific excellence, responsibility and accountability. We invite you to explore our organization, and we are confident you will share our values and are interested in becoming a member, devoting your time or efforts, or sponsoring CABA activities. In summary, CABA is built by its members and serves for its members.


Contact Us

Your Name: *
Your Email: *
Cell phone:
Subject: *
Message: *